This immunosuppressive effect could be reversed through pharmacological inhibition of tyrosine kinase inhibitor (TKI) that blocks vascular endothelial growth factor receptors 1, 2, and 3 (VEGFR1, VEGFR2, and VEGFR3) in tumor models [107]. The gene discussed is KDR; the disease is neoplasm.